15
Participants
Start Date
June 19, 2017
Primary Completion Date
August 16, 2018
Study Completion Date
August 16, 2018
⁸⁹Zr-Df-IAB22M2C Infusion
A single dose of 3.0 (±20%) mCi of ⁸⁹Zr-Df-IAB22M2C (with 0.2 mg, 0.5 mg, 1.0mg, 1.5 mg, 5.0 mg, or 10.0 mg of protein) will be administered intravenously over 5-10 minutes.
Memorial Sloan Kettering Cancer Center, New York
University of Pennsylvania, Philadelphia
Honor Health and Imaging Endpoints, Scottsdale
Lead Sponsor
ImaginAb, Inc.
INDUSTRY